Comparing the Diagnostic Performance of [18F]PSMA-1007 With [68Ga]Ga-PSMA-11 in PET/CT Imaging and Staging of Recurrent Prostate Cancer

Negar Abdi, Miad Alsulami, Hamid Ghaznavi
{"title":"Comparing the Diagnostic Performance of [18F]PSMA-1007 With [68Ga]Ga-PSMA-11 in PET/CT Imaging and Staging of Recurrent Prostate Cancer","authors":"Negar Abdi,&nbsp;Miad Alsulami,&nbsp;Hamid Ghaznavi","doi":"10.1002/med4.70006","DOIUrl":null,"url":null,"abstract":"<p>PET/CT has become the reference standard imaging modality for diagnosing prostate cancer because of its ability to target prostate-specific membrane antigen (PSMA), a protein specific to prostate cells. [<sup>68</sup>Ga]Ga-PSMA-11 was a major advance, but limitations such as a short lifespan and image blurring led to the introduction of [<sup>18</sup>F]PSMA-1007, which offers advantages such as a longer lifespan and clearer images. This study aimed to compare the effectiveness of [<sup>18</sup>F]PSMA-1007 and [<sup>68</sup>Ga]Ga-PSMA-11 in the detection and staging of recurrent prostate cancer because there is currently insufficient evidence to conclude that one PSMA-radiotracer is better than the other. Both <sup>68</sup>Ga and <sup>18</sup>F-labeled PSMA-radiotracers have similar detection rates in patients. Therefore, more investigation is required to authoritatively conclude which radiotracer results in optimal performance for diagnosing prostate cancer lesions on PET/CT. In this narrative review, we focus on comparing the effectiveness of [<sup>18</sup>F]PSMA-1007 with that of [<sup>68</sup>Ga]Ga-PSMA-11 in the detection of recurrent prostate cancer and determination of its stage. We found that [<sup>18</sup>F]PSMA-1007 and [<sup>68</sup>Ga]Ga-PSMA-11 showed similar diagnostic performance, with [<sup>18</sup>F]PSMA-1007 having slightly higher sensitivity for primary and metastatic recurrent prostate cancer. However, a lack of statistical significance in the differences between the two radiotracers indicates comparable diagnostic accuracy, enabling their interchangeable use based on availability and cost efficiency.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 1","pages":"9-19"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70006","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine Advances","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/med4.70006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

PET/CT has become the reference standard imaging modality for diagnosing prostate cancer because of its ability to target prostate-specific membrane antigen (PSMA), a protein specific to prostate cells. [68Ga]Ga-PSMA-11 was a major advance, but limitations such as a short lifespan and image blurring led to the introduction of [18F]PSMA-1007, which offers advantages such as a longer lifespan and clearer images. This study aimed to compare the effectiveness of [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 in the detection and staging of recurrent prostate cancer because there is currently insufficient evidence to conclude that one PSMA-radiotracer is better than the other. Both 68Ga and 18F-labeled PSMA-radiotracers have similar detection rates in patients. Therefore, more investigation is required to authoritatively conclude which radiotracer results in optimal performance for diagnosing prostate cancer lesions on PET/CT. In this narrative review, we focus on comparing the effectiveness of [18F]PSMA-1007 with that of [68Ga]Ga-PSMA-11 in the detection of recurrent prostate cancer and determination of its stage. We found that [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 showed similar diagnostic performance, with [18F]PSMA-1007 having slightly higher sensitivity for primary and metastatic recurrent prostate cancer. However, a lack of statistical significance in the differences between the two radiotracers indicates comparable diagnostic accuracy, enabling their interchangeable use based on availability and cost efficiency.

Abstract Image

PET/CT 能够靶向前列腺细胞特异性蛋白--前列腺特异性膜抗原 (PSMA),因此已成为诊断前列腺癌的参考标准成像方式。[68Ga]Ga-PSMA-11是一项重大进步,但由于其寿命短、图像模糊等局限性,[18F]PSMA-1007应运而生,它具有寿命长、图像更清晰等优点。本研究旨在比较[18F]PSMA-1007和[68Ga]Ga-PSMA-11在复发性前列腺癌的检测和分期中的有效性,因为目前还没有足够的证据来断定一种PSMA-放射示踪剂优于另一种。68Ga和18F标记的PSMA放射示踪剂在患者体内的检出率相似。因此,需要进行更多的研究,才能权威地得出结论,哪种放射性示踪剂在 PET/CT 诊断前列腺癌病灶方面性能最佳。在这篇综述中,我们重点比较了[18F]PSMA-1007与[68Ga]Ga-PSMA-11在检测复发性前列腺癌并确定其分期方面的效果。我们发现[18F]PSMA-1007和[68Ga]Ga-PSMA-11具有相似的诊断性能,其中[18F]PSMA-1007对原发性和转移性复发性前列腺癌的敏感性略高。不过,两种放射性核素之间的差异缺乏统计学意义,这表明它们的诊断准确性相当,因此可以根据可用性和成本效益互换使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信